Filing Details
- Accession Number:
- 0001104659-13-038318
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-05-07 17:39:42
- Reporting Period:
- 2013-04-25
- Filing Date:
- 2013-05-07
- Accepted Time:
- 2013-05-07 17:39:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1526119 | Verastem Inc. | VSTM | Pharmaceutical Preparations (2834) | 273269467 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1291961 | H Christoph Westphal | C/O Verastem, Inc., 215 First Street, Suite 440 Cambridge MA 02142 | Chief Executive Officer | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-04-25 | 287 | $9.89 | 702,376 | No | 4 | L | Direct | |
Common Stock | Acquisiton | 2013-04-25 | 513 | $9.90 | 702,889 | No | 4 | L | Direct | |
Common Stock | Acquisiton | 2013-05-03 | 800 | $9.83 | 703,689 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | L | Direct | |
No | 4 | L | Direct | |
No | 4 | P | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 2,869,841 | Indirect | By Longwood Fund, L.P. |
Common Stock | 125,714 | Indirect | By the Fountain Irrevocable Trust of 2010 |
Footnotes
- The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 20, 2012.
- Represents a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $9.76 to $9.905, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 2 to this Form 4.
- Longwood Fund GP, LLC is the sole General Partner of Longwood Fund, L.P. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the issuer's securities held by Longwood Fund L.P. (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of the Longwood Shares in this report shall not be deemed an admission of beneficial ownership of the Longwood Shares for purposes of Section 16 or for any other purpose.